116986-14-2Relevant articles and documents
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 0371, (2021/07/31)
Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).
AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS
-
, (2014/02/16)
The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.
Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication
Skerlj, Renato,Bridger, Gary,McEachern, Ernie,Harwig, Curtis,Smith, Chris,Wilson, Trevor,Veale, Duane,Yee, Helen,Crawford, Jason,Skupinska, Krystyna,Wauthy, Rossana,Yang, Wen,Zhu, Yongbao,Bogucki, David,Di Fluri, Maria,Langille, Jonathon,Huskens, Dana,De Clercq, Erik,Schols, Dominique
scheme or table, p. 262 - 266 (2011/02/27)
An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca2+ flux
